Psychedelics and Hallucinogens in Psychiatry - Conversations with Prof David Nutt скачать в хорошем качестве

Psychedelics and Hallucinogens in Psychiatry - Conversations with Prof David Nutt

Dr Sanil Rege talks with Prof David Nutt, an expert in the field of Psychedelic research. Prof David Nutt is currently head of Neuropsychopharmacology at Imperial College London and Chair of the Charity Drug Science. Prof Nutt uses brain imaging research to explore the effects of drugs in the brain and the mechanisms of addiction and depression. Under his leadership, the psychedelic research group at Imperial College has become one of the world's foremost psychedelic research laboratories, publishing landmark research on the neuroscience of psychedelic and from these develop new therapies for mental illness. Dr Sanil Rege is a Consultant Psychiatrist and founder of Psych Scene and Vita Healthcare. Psychedelics are any of the so-called mind-expanding drugs that can induce states of altered perception and thoughts, frequently with a heightened awareness of sensory input but with diminished control over what is being experienced. [Rucker J et al., 2018] Hallucinogens were originally referred to as psychotomimetics after Isbell and colleagues described lysergic acid diethylamide (LSD) as “the most effective and safest agent for inducing an experimental, but reversible, psychosis in nonpsychotic subjects”. [Isbell et al. 1956] However, in the 1940s and 1950s, LSD was also being trialled as a psychotherapeutic agent for treating depression and anxiety. Take-home messages: 1. Despite the controversial history of psychedelic therapy, clinical studies have described the therapeutic benefits of psychedelic experiences in a safe and supportive environment. 2. Reclassification of psychedelics as a schedule II drug will enable further clinical research and the possible discovery of novel benefits of psychedelic administration in psychiatric disorders. 3. Worldwide, about 100 psychedelic trials are currently active to treat depression and anxiety in the terminally ill, alcohol and drug use disorders, dementia, anorexia and chronic pain. 4. The UK, Canada, the United States, and Israel are active research hubs, and international collaboration is informed. The first psilocybin-assisted psychotherapy trial has been approved in Australia, targeting depressive and anxious symptoms in terminal patients, and is hosted at St Vincent’s Hospital, Melbourne. [Clinical Memorandum, RANZCP] 5. Psychedelic substances are illicit and are not registered for any use by the Therapeutic Goods Administration (TGA) in Australia or Medsafe in New Zealand. 6. Further research is required to assess psychedelic therapies' efficacy, safety, and effectiveness to inform future potential use in psychiatric practice.